170 related articles for article (PubMed ID: 29614078)
1. A bi-stable feedback loop between GDNF, EGR1, and ERα contribute to endocrine resistant breast cancer.
Horibata S; Rice EJ; Zheng H; Mukai C; Chu T; Marks BA; Coonrod SA; Danko CG
PLoS One; 2018; 13(4):e0194522. PubMed ID: 29614078
[TBL] [Abstract][Full Text] [Related]
2. GDNF-RET signaling and EGR1 form a positive feedback loop that promotes tamoxifen resistance via cyclin D1.
Marks BA; Pipia IM; Mukai C; Horibata S; Rice EJ; Danko CG; Coonrod SA
BMC Cancer; 2023 Feb; 23(1):138. PubMed ID: 36765275
[TBL] [Abstract][Full Text] [Related]
3. GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
Morandi A; Martin LA; Gao Q; Pancholi S; Mackay A; Robertson D; Zvelebil M; Dowsett M; Plaza-Menacho I; Isacke CM
Cancer Res; 2013 Jun; 73(12):3783-95. PubMed ID: 23650283
[TBL] [Abstract][Full Text] [Related]
4. Regulation of p130(Cas)/BCAR1 expression in tamoxifen-sensitive and tamoxifen-resistant breast cancer cells by EGR1 and NAB2.
Kumbrink J; Kirsch KH
Neoplasia; 2012 Feb; 14(2):108-20. PubMed ID: 22431919
[TBL] [Abstract][Full Text] [Related]
5. Structural and Molecular Mechanisms of Cytokine-Mediated Endocrine Resistance in Human Breast Cancer Cells.
Stender JD; Nwachukwu JC; Kastrati I; Kim Y; Strid T; Yakir M; Srinivasan S; Nowak J; Izard T; Rangarajan ES; Carlson KE; Katzenellenbogen JA; Yao XQ; Grant BJ; Leong HS; Lin CY; Frasor J; Nettles KW; Glass CK
Mol Cell; 2017 Mar; 65(6):1122-1135.e5. PubMed ID: 28306507
[TBL] [Abstract][Full Text] [Related]
6. HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.
Jin K; Park S; Teo WW; Korangath P; Cho SS; Yoshida T; Győrffy B; Goswami CP; Nakshatri H; Cruz LA; Zhou W; Ji H; Su Y; Ekram M; Wu Z; Zhu T; Polyak K; Sukumar S
Cancer Discov; 2015 Sep; 5(9):944-59. PubMed ID: 26180042
[TBL] [Abstract][Full Text] [Related]
7. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
8. Cyclin dependent kinase-9 mediated transcriptional de-regulation of cMYC as a critical determinant of endocrine-therapy resistance in breast cancers.
Sengupta S; Biarnes MC; Jordan VC
Breast Cancer Res Treat; 2014 Jan; 143(1):113-24. PubMed ID: 24309997
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
[TBL] [Abstract][Full Text] [Related]
10. The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1.
Cairns J; Ingle JN; Kalari KR; Shepherd LE; Kubo M; Goetz MP; Weinshilboum RM; Wang L
Breast Cancer Res; 2019 Apr; 21(1):47. PubMed ID: 30944027
[TBL] [Abstract][Full Text] [Related]
11. VAV3 mediates resistance to breast cancer endocrine therapy.
Aguilar H; Urruticoechea A; Halonen P; Kiyotani K; Mushiroda T; Barril X; Serra-Musach J; Islam A; Caizzi L; Di Croce L; Nevedomskaya E; Zwart W; Bostner J; Karlsson E; Pérez Tenorio G; Fornander T; Sgroi DC; Garcia-Mata R; Jansen MP; García N; Bonifaci N; Climent F; Soler MT; Rodríguez-Vida A; Gil M; Brunet J; Martrat G; Gómez-Baldó L; Extremera AI; Figueras A; Balart J; Clarke R; Burnstein KL; Carlson KE; Katzenellenbogen JA; Vizoso M; Esteller M; Villanueva A; Rodríguez-Peña AB; Bustelo XR; Nakamura Y; Zembutsu H; Stål O; Beijersbergen RL; Pujana MA
Breast Cancer Res; 2014 May; 16(3):R53. PubMed ID: 24886537
[TBL] [Abstract][Full Text] [Related]
12. An H3K4me3 reader, BAP18 as an adaptor of COMPASS-like core subunits co-activates ERα action and associates with the sensitivity of antiestrogen in breast cancer.
Sun G; Wang C; Wang S; Sun H; Zeng K; Zou R; Lin L; Liu W; Sun N; Song H; Liu W; Zhou T; Jin F; Shan Z; Zhao Y
Nucleic Acids Res; 2020 Nov; 48(19):10768-10784. PubMed ID: 32986841
[TBL] [Abstract][Full Text] [Related]
13. MLL3 is a de novo cause of endocrine therapy resistance.
Stauffer KM; Elion DL; Cook RS; Stricker T
Cancer Med; 2021 Nov; 10(21):7692-7711. PubMed ID: 34581028
[TBL] [Abstract][Full Text] [Related]
14. Estrogen-independent Myc overexpression confers endocrine therapy resistance on breast cancer cells expressing ERαY537S and ERαD538G mutations.
Yu L; Wang L; Mao C; Duraki D; Kim JE; Huang R; Helferich WG; Nelson ER; Park BH; Shapiro DJ
Cancer Lett; 2019 Feb; 442():373-382. PubMed ID: 30419347
[TBL] [Abstract][Full Text] [Related]
15. MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelial-mesenchymal transition, decreased ERα expression and AKT activation.
Liang YK; Zeng D; Xiao YS; Wu Y; Ouyang YX; Chen M; Li YC; Lin HY; Wei XL; Zhang YQ; Kruyt FA; Zhang GJ
Cancer Lett; 2017 Feb; 386():65-76. PubMed ID: 27838413
[TBL] [Abstract][Full Text] [Related]
16. Expression of the CD59 Glycoprotein Precursor is Upregulated in an Estrogen Receptor-alpha (ER-α)-Negative and a Tamoxifen-Resistant Breast Cancer Cell Line In Vitro.
Xiong H; Jin X; You C
Med Sci Monit; 2018 Nov; 24():7883-7890. PubMed ID: 30391994
[TBL] [Abstract][Full Text] [Related]
17. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
[No Abstract] [Full Text] [Related]
18. The ubiquitin ligase RNF181 stabilizes ERα and modulates breast cancer progression.
Zhu J; Li X; Su P; Xue M; Zang Y; Ding Y
Oncogene; 2020 Oct; 39(44):6776-6788. PubMed ID: 32973333
[TBL] [Abstract][Full Text] [Related]
19. c-Jun/AP-1 overexpression reprograms ERα signaling related to tamoxifen response in ERα-positive breast cancer.
He H; Sinha I; Fan R; Haldosen LA; Yan F; Zhao C; Dahlman-Wright K
Oncogene; 2018 May; 37(19):2586-2600. PubMed ID: 29467493
[TBL] [Abstract][Full Text] [Related]
20. KLF17 attenuates estrogen receptor α-mediated signaling by impeding ERα function on chromatin and determines response to endocrine therapy.
Ali A; Ielciu I; Alkreathy HM; Khan AA
Biochim Biophys Acta; 2016 Jul; 1859(7):883-95. PubMed ID: 27107895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
